Biomarin Pharmaceutical

Region Nordamerika
ISIN US09061G1013
Sektor Biotechnologie
Website http://www.biomarin.com

BioMarin Pharmaceutical ist ein Biotech-Unternehmen mit Sitz in San Rafale. BioMarin war das erste Unternehmen welches eine Therapie für Mukopolysaccharidose und Phenylketonurie entwickelt hat.


News

Titel Datum
Biomarin Pharmaceutical Inc. Bottom Line Rises In Q2
WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) announced a profit for its second qua...
vor 23 Tagen
BioMarin Q2 2025 slides: Revenue up 16%, EPS soars 124% as margins expand vor 23 Tagen
BioMarin Pharmaceutical Non-GAAP EPS of $1.44 beats by $0.43, revenue of $825M beats by $63.34M vor 23 Tagen
BioMarin Pharmaceutical Inc.: BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance for Total Revenues, Non-G...
Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) ...
vor 24 Tagen
BIOMARIN PHARMACEUTICAL INC - 8-K, Current Report vor 26 Tagen